KAL
In a world first, KAL ATM Software and Česká spořitelna have rolled out the first ATM running Windows 10 on a Linux Hypervisor.
KAL’s new Kalignite Hypervisor solution, in partnership with Red Hat, is a game-changing solution that allows banks to break free from enforced, costly and disruptive ATM hardware upgrades.
It uses OS-Virtualization technology to solve the long-standing problem of enforced ATM hardware upgrades and decouples the ATM PC-core from the ATM operating system so that software drivers that are unsupported under new Windows operating system versions can be supported by the Linux drivers instead.
Česká spořitelna’s ATM Software Innovation product owner, Jakub Otáhal, explains that the end of support for Windows 7, and the accompanying expense and complexity of upgrading ATM hardware and software to Windows 10, prompted the decision to install Kalignite Hypervisor in a pilot production environment.
He said: “KAL’s new solution gives Česká spořitelna control over when to carry out hardware upgrades. This means we can cut costs by keeping to our 10-11 year renewal recycle, rather than being forced to comply with the hardware lifetime. Very importantly, Kalignite Hypervisor also enables us to keep our software right up to date.”
KAL CEO Aravinda Korala added: “We are delighted that Česká spořitelna decided to partner with us to achieve this impressive world first. Kalignite Hypervisor enables Česká spořitelna to stay completely up to date and run the latest versions of all software on their ATMs. Not only does this technology help with the Windows 10 migration, it also allows Česká spořitelna to migrate to new Windows LTSC and SAC upgrades without requiring hardware changes.”
About Česká spořitelna
Česká spořitelna is the largest bank in the Czech Republic with more than four million clients and the most extensive branch and ATM networks in the country. It provides services for individuals, small and medium-sized enterprises, towns and municipalities, and finances large corporations.
Česká spořitelna is proud of its long tradition – it was established in 1825 as the first savings bank in the Czech Republic – but it is equally proud of its role as an innovator. Many of its products and services are leaders in the Czech market. The bank has been a member of the Erste Group since 2000.
For more information, visit www.csas.cz/en/about-us/who-we-are
About KAL
KAL is a world-leading ATM software company and the preferred supplier to mega-banks such as Citibank, UniCredit, ING and China Construction Bank.
KAL’s software gives banks full control of their ATM network, reducing costs, meeting all security needs and improving competitiveness. It is installed and supported in more than 80 countries.
For more information, visit www.kal.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200115005065/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aspect Announces CEO Leadership Transition and New Independent Board7.1.2026 00:13:00 CET | Press release
Aspect, a leading provider of cloud-based workforce management solutions, has announced a leadership transition, including the appointment of Jeff Kupietzky as Interim Chief Executive Officer and the formation of a new independent Board of Directors, marking an important next chapter for the company. As part of this transition, Darryl Kelly will step down as Chief Executive Officer and transition into a Strategic Advisor role, effective January 1, 2026. Darryl led Aspect through a pivotal period of transformation, helping reposition the business, refine its vision, and reinvigorate its innovation and execution. The company and its stakeholders thank Darryl for his leadership and contributions during a period of meaningful change. With Darryl continuing as Strategic Advisor, the organization retains continuity for employees, customers, and stakeholders. “Aspect is starting a new season, building upon the strong foundation we’ve created together,” said Darryl Kelly. “This transition is a
Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients6.1.2026 21:00:00 CET | Press release
Brenus Pharma, a clinical stage biotechnology company unlocking the immune system in vivo to fight solid tumors, announced the successful completion of the first dose levels in its ongoing first-in-human study. The multi-center, open-label trial (NCT06934538) is a phase Ia/Ib study designed to evaluate safety, tolerability and preliminary clinical activity of STC-10101 in a first line setting. It will include in vivo analysis of immune and tumor dynamics during dose escalation of treatment and cohort extension to patients with unresectable locally advanced (stage IIIC, T4b) or unresectable metastatic (stage IV) MSS2 colorectal cancer (CRC). Early findings indicate that the first dose levels have been successfully completed with good overall tolerance and no-dose-limiting toxicities observed to date. “We are pleased to report that the safety profile observed to date is good and consistent with our expectations with no DLT,” said Paul Bravetti, CEO of Brenus Pharma. “Moreover, preliminar
SPIE, the International Society for Optics and Photonics, Announces Its 2026 Fellows6.1.2026 20:35:00 CET | Press release
The Society is welcoming 40 new Fellow Members from across the globe SPIE, the international society for optics and photonics, welcomes 40 Members as new Fellows of the Society in the 2026 cohort. They join their Fellow Member colleagues in being honored for their excellent technical achievements, as well as for their substantial service to the optics and photonics community and to SPIE. Fellows are Members of the Society who have made significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, and imaging. Since the Society's inception in 1955, more than 1,800 SPIE Members have become Fellows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106630672/en/ SPIE, the international society for optics and photonics, announces its 2026 Fellows This year’s inductees are high-profile leaders in academia, industry, and government, many of whom are particularly prominent in their support
Chemelex Adds Electric Heat Trace Group Ltd.’s SmartTrace Monitoring Platform to its Heat Tracing Portfolio6.1.2026 20:00:00 CET | Press release
Chemelex, a global leader in electric thermal and sensing solutions, today announced the successful completion of its acquisition of substantially all the assets and ongoing operations of Electric Heat Trace Group Ltd. (EHT Group), headquartered in Ontario, Canada. This strategic move marks an exciting start to the new year and reinforces Chemelex’s commitment to delivering smarter, data-driven solutions for industrial heat trace systems. EHT Group is a recognized innovator in heat trace management, offering advanced software, integrated controller solutions, wireless communication modules, and comprehensive field services. Its flagship platform, SmartTrace, is a robust solution available in both cloud-based and on-premises deployments that enables predictive maintenance, minimizes downtime, and provides secure remote monitoring—helping customers achieve greater reliability and operational efficiency. This endeavor will help Chemelex support greater operational efficiencies for our cus
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA6.1.2026 19:30:00 CET | Press release
Combination therapy showed compelling survival and disease control compared to current standard, regardless of PD-L1 statusHigh GEA burden in Asia, where BeOne holds ZIIHERA rights, signals potential broad patient impactResults to be presented as a Late-Breaking Abstract Oral Presentation at ASCO GI on January 8, 2026 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, including the first interim overall survival (OS) analysis, will be presented as a Late-Breaking Abstract Oral Presentation (#LBA285) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom